Publications by the researcher in collaboration with José Manuel Cózar Olmo (20)

2023

  1. Hormone sensitive protocol for metastatic prostate cancer, an update

    Actas Urologicas Espanolas, Vol. 47, Núm. 4, pp. 244-249

2022

  1. Efficacy and Safety of the Hexanic Extract of Serenoa repens vs. Watchful Waiting in Men with Moderate to Severe LUTS-BPH: Results of a Paired Matched Clinical Study

    Journal of Clinical Medicine, Vol. 11, Núm. 4

  2. Efficacy and Tolerability of 6-Month Treatment with Tamsulosin Plus the Hexanic Extract of Serenoa repens versus Tamsulosin Plus 5-Alpha-Reductase Inhibitors for Moderate-to-Severe LUTS-BPH Patients: Results of a Paired Matched Clinical Study

    Journal of Clinical Medicine, Vol. 11, Núm. 13

2021

  1. Efficacy and tolerability of the hexanic extract of Serenoa repens compared to tamsulosin in moderate-severe LUTS-BPH patients

    Scientific Reports, Vol. 11, Núm. 1

2020

  1. Clinical benefit of tamsulosin and the hexanic extract of serenoa repens, in combination or as monotherapy, in patients with moderate/severe luts-bph: A subset analysis of the qualiprost study

    Journal of Clinical Medicine, Vol. 9, Núm. 9, pp. 1-14

2019

  1. Factors related to early castration resistance in metastatic prostate cancer. Results from the National Prostate Cancer Registry in Spain

    Actas Urologicas Espanolas, Vol. 43, Núm. 10, pp. 562-567

  2. Three-year interim results of overall and progression-free survival in a cohort of patients with prostate cancer (GESCAP group)

    Actas Urologicas Espanolas, Vol. 43, Núm. 1, pp. 4-11

2018

  1. Radium-223 for the treatment of metastatic castration-resistant prostate cancer: A window of opportunity

    Actas Urologicas Espanolas

2017

  1. Cáncer de próstata resistente a la castración. Recomendaciones de consenso de la Asociación Española de Urología

    Actas Urologicas Espanolas

  2. Diagnosis and treatment for clinically localized prostate cancer. Adherence to the European Association of Urology clinical guidelines in a nationwide population-based study – GESCAP group

    Actas Urologicas Espanolas, Vol. 41, Núm. 6, pp. 359-367

2016

  1. Influence of demographic and tumour variables on prostate cancer treatment with curative intent in Spain. Results of the 2010 national prostate cancer registry

    Actas Urologicas Espanolas, Vol. 40, Núm. 8, pp. 485-491

  2. Tendencias de tratamiento en el cáncer de próstata clínicamente localizado. Análisis poblacional a nivel nacional: grupo GESCAP

    Actas Urologicas Espanolas, Vol. 40, Núm. 4, pp. 209-216

2015

  1. Adherencia a las recomendaciones sobre la linfadenectomía de las guías clínicas del 2009 en el Registro Nacional de Cáncer de Próstata-2010

    Actas Urologicas Espanolas, Vol. 39, Núm. 9, pp. 546-552

2014

  1. Bone health in patients with prostate cancer

    Actas urologicas espanolas

2013

  1. Registro nacional de cáncer de próstata 2010 en España

    Actas Urologicas Espanolas, Vol. 37, Núm. 1, pp. 12-19

  2. Treatment of prostate and renal cancer with oral drugs (abiratarone and antiangiogenic agents): Positioning statement from the Spanish Association of Urology

    Actas Urologicas Espanolas

2012

  1. Consenso sobre el impacto clínico de la nueva evidencia científica disponible sobre hiperplasia benigna prostática

    Actas Urologicas Espanolas, Vol. 36, Núm. 5, pp. 265-275

  2. Prostate cancer incidence and newly diagnosed patient profile in Spain in 2010

    BJU International, Vol. 110, Núm. 11 B

2008

  1. Efectividad y tolerabilidad del ácido zoledrónico en el tratamiento del cancer de próstata metastásico

    Actas Urologicas Espanolas, Vol. 32, Núm. 5, pp. 492-501

2005

  1. Cáncer de próstata de alto riesgo y diseminado (Documento de Consenso de Recomendaciones)

    Actas Urologicas Espanolas, Vol. 29, Núm. 9, pp. 826-827